Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...
In this Healio Video Perspective from Retina 2025, W. Lloyd Clark, MD, discusses positive results from three clinical trials investigating NT-501 for macular telangiectasia type 2.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback